{
    "organizations": [],
    "uuid": "681b0a764f8b5f8b8fff00fda64f8d42b127023b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-astrazeneca-says-us-fda-accepts-bl/brief-astrazeneca-says-u-s-fda-accepts-bla-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia-idUSFWN1RG01K",
    "ord_in_thread": 0,
    "title": "BRIEF-Astrazeneca Says ‍U.S. FDA Accepts BLA For Moxetumomab Pasudotox In Hairy Cell Leukaemia​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Astrazeneca Plc:\n* ‍US FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR MOXETUMOMAB PASUDOTOX IN HAIRY CELL LEUKAEMIA​\n* ‍PHASE III MOXETUMOMAB PASUDOTOX CLINICAL TRIAL MET ITS PRIMARY ENDPOINT​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-03T09:56:00.000+03:00",
    "crawled": "2018-04-03T10:17:36.080+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "astrazeneca",
        "plc",
        "fda",
        "accepts",
        "biologics",
        "license",
        "application",
        "moxetumomab",
        "pasudotox",
        "hairy",
        "cell",
        "iii",
        "moxetumomab",
        "pasudotox",
        "clinical",
        "trial",
        "met",
        "primary",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}